Countdown Widget

Join Us

2019/04/05 08:00:00

Program Details

Location: Kay Auditorium at Roger Williams Medical Center

View Map
Date: April 5, 2019
Time: 8:00 AM -2:45 PM

8:00—8:35 a.m. Registration and Breakfast

In-person registration available day of conference. Continental Breakfast provided.

8:35—8:50 a.m. Welcome and Opening Statements

8:509:35 a.m. State of Addiction, Elizabeth A. Samuels, MD, MPH, MHS, RI Department of Health

9:3510:20 a.m. Epidemiological Profile, Alan Epstein, MD, Roger Williams Medical Center

10:20—10:30 a.m. Break

10:30—11:15 a.m. Hepatitis C Treatment: Update from Center for Health Law & Policy Innovation, Phil Waters, JD, Center for Health Law and Policy Innovation

11:15 a.m.—12:00 p.m. Approach to HCV Treatment: Lessons learned from the Clinic, Thomas E. Sepe, MD, University Gastroenterology


12:00—1:00 p.m. Lunch

1:00—1:45 p.m. Harm Reduction Approach, Raynald Joseph, Prevention Supervisor, AIDS Care Ocean State

1:45—2:30 p.m. Barriers to Recovery and Care, Jonathan Goyer, Manager, Anchor MORE, The Providence Center

2:30-2:45 p.m. Closing Statements


Considerations for Antiretroviral Use in Patients With Coinfections: Hepatitis C Virus/HIV Coinfection. US Department of Health and Human Services (DHHS), 2017 (last updated March 2018).

Patients With HIV/HCV Coinfection. American Association for the Study of Liver Diseases (AASLD)/Infectious Diseases Society of America (IDSA), 2017.

Getting Off Right: A Safety Manual for Injection Drug Users: Harm Reduction Coalition. The Harm Reduction Coalition has produced a compilation of unbiased medical facts, injection techniques, and common sense with the goal of reducing harm and promoting individual and community health.

Hep C 123: Diagnosis, Treatment & Support: American Liver Foundation, 2018. The American Liver Foundation’s Hep C 123 website is a dedicated online information and resource center created in support of individuals impacted by HCV infection.

Project Inform: Project Inform provides up-to-date information to help people living with HIV and HCV make the best choices regarding their treatment and care.

Hepatitis C and HIV Coinfection Booklets

Sex-C: Sex and Hepatitis C Prevention Tips for Gay Men

Sexual Transmission of Hepatitis C: A Guide for HIV-Positive Gay Men

Incidence of sexually transmitted hepatitis C virus infection in HIV-positive men who have sex with men: a systematic review and meta-analysis. Hagan H, et al. AIDS. 2015;29(17):2335-2345.

Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006–2012. Suryaprasad AG, et al. Clin Infect Dis. 2014;59(10):1411-1419.

Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination. Virlogeux V, et al. BMC Med. 2017;15(1):217.

Mechanisms of accelerated liver fibrosis progression during HIV infection. Debes JD, et al. J Clin Transl Hepatol. 2016;4(4):328-335.

HCV coinfection contributes to HIV pathogenesis by increasing immune exhaustion in CD8 T-cells. Rallón N, et al. PLoS One. 2017;12(3):e0173943.

Emerging and underrecognized complications of illicit drug use.  Wurcel AG, et al. Clin Infect Dis. 2015;61(12):1840-1849.

Attitudes and potential barriers towards hepatitis C treatment in patients with and without HIV coinfection. Allyn PR, et al. Int J STD AIDS. 2018;29(4):334-340.

Behavioural, not biological, factors drive the HCV epidemic among HIV-positive MSM: HCV and HIV modelling analysis including HCV treatment-as-prevention impact.  MacGregor L, et al. Int J Epidemiol. 2017;46(5):1582-1592.

HIV/HCV co-infection: new guidelines, opportunities & challenges with the incarcerated population in the U.S. Fisher N. HIV Specialist. 2017;9(1):16-19.

Barriers to hepatitis C antiviral therapy in HIV/HCV co-infected patients in the United States: a review.  Oramasionwu CU, et al. AIDS Patient Care STDS. 2014;28(5):228-239.

Effectiveness of all-oral antiviral regimens in 996 human immunodeficiency virus/hepatitis C virus genotype 1-coinfected patients treated in routine practice. Bhattacharya D, et al. Clin Infect Dis. 2017;64(12):1711-1720.

HCV mono-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ? Bruno G, et al. Int J Infect Dis. 2017;62:64-71.

Direct-acting antivirals improve access to care and cure for patients with HIV and chronic HCV infection. Collins LF, et al. Open Forum Infect Dis. 2017;5(1):ofx264.

High hepatitis C cure rates among black and nonblack human immunodeficiency virus–infected adults in an urban center. Falade-Nwulia O, et al. Hepatology. 2017;66(5):1402-1412.

Medical and behavioral approaches to engage people who inject drugs into care for hepatitis C virus infection. Gonzalez SA, et al. Addict Disord Their Treat. 2017;16(2 suppl 1):S1-S23.

Interferon-free therapy for treating hepatitis C virus in difficult-to-treat HIV-coinfected patients. Mínguez C, et al. AIDS. 2018;32(3):337-346.

Efficacy and safety of glecaprevir/pibrentasvir in patients co-infected with hepatitis C virus and human immunodeficiency virus-1: the EXPEDITION-2 study. Rockstroh JK, et al. Clin Infect Dis. 2018. (Epub ahead of print).

Patient-reported outcomes in patients co-infected with hepatitis C virus and human immunodeficiency virus treated with sofosbuvir and velpatasvir: The ASTRAL-5 study. Younossi ZM, et al. Liver Int. 2017;37(12):1796-1804.

The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection. Zeuzem S, et al. J Gastroenterol. 2018;53(5):679-688.

Hepatitis C virus re-treatment in the era of direct-acting antivirals: projections in the USA. Chhatwal J, et al. Aliment Pharmacol Ther. 2018;47(7):1023-1031.

The HCV care continuum does not end with cure: a call to arms for the prevention of reinfection. Falade-Nwulia O, Sulkowski M. J Hepatol. 2017;66(2):267-269.

Treatment of HCV in persons who inject drugs: treatment as prevention.  Grebely J, Dore GJ. Clin Liver Dis. 2017;9(4):77-80.

Risk factors for hepatitis C virus reinfection after sustained virologic response in patients coinfected with HIV. Young J, et al. Clin Infect Dis. 2017;64(9):1154-1162.

Comments are closed.